Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230023 | 0.90 | LMNA (0.59) | LMNAHTTNPSR1SMN1; SMN2KMT2A | |
| SCHEMBL2793841 | 0.88 | LMNA (0.55) | LMNAHTTNPSR1SMN1; SMN2KMT2A | |
| SCHEMBL2789869 | 0.86 | LMNA (0.52) | LMNAHTTNPSR1SMN1; SMN2KMT2A | |
| SCHEMBL10253824 | 0.84 | CYP1A2 (0.52) | LMNAHTTNPSR1SMN1; SMN2HPGD | |
| SCHEMBL9056505 | 0.83 | NPC1 (0.57) | LMNASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19388337 | 0.82 | CTSS (0.56) | LMNAMEN1KMT2ACTSLCTSB | |
| SCHEMBL15113139 | 0.82 | CTSS (0.56) | LMNAMEN1KMT2ACTSLCTSB | |
| SCHEMBL192484 | 0.81 | PLAU (0.64) | LMNAHTTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL28047575 | 0.81 | PLAU (0.64) | LMNAHTTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL12159688 | 0.81 | KMT2A (0.58) | LMNASMN1; SMN2HPGDMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190788-A1 | Amide derivatives as kinase inhitors | DEVGEN N.V. (BE) | 2010-07-29 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| EP-1907361-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | Devgen N.V. (BE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1907362-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | Devgen NV (BE) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007006547-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006546-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | LMNA 1207/4885HTT 1022/4885NPSR1 886/4885 |
| US-20100190788-A1 | Amide derivatives as kinase inhitors | MAP3K1, MAPK1, MAP3K21 | LMNA 762/4885HTT 875/4885NPSR1 1532/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | LMNA 1207/4885HTT 1022/4885NPSR1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.